Human melanoma: development and progression
- PMID: 2253310
- DOI: 10.1007/BF00046337
Human melanoma: development and progression
Abstract
Clinical and histopathological evidence suggests that melanoma develops in a sequence of steps, progressing from benign proliferative lesions, to primary melanomas that do not show evidence for metastasis, to invasive primary lesions, and to metastases. This review focuses on the experimental studies examining the phenotypic characteristics of cultured primary melanoma cells as they relate to cells from non-malignant nevi and metastases. Genetic, biologic, and immunologic criteria have been established to distinguish melanocytes from different steps of tumor development. These include non-random chromosomal abnormalities, expression of melanocyte- and melanoma-specific antigens, requirements for exogenous growth factors, production of endogenous growth factors, and expression of receptors for growth factors. The transformation of melanocytes and nevus cells with viral oncogenes has facilitated studies on the malignant phenotype. Variants have been developed through successive selections from primary melanoma cell populations that have one or several characteristics of metastatic cells. The study of melanocytes isolated from various stages of tumor development and the generation of cell variants with specific properties should enable a long-term search for the molecular mechanisms of melanoma development and progression.
Similar articles
-
Tumor progression in the human melanocytic system.Anticancer Res. 1989 Jul-Aug;9(4):865-72. Anticancer Res. 1989. PMID: 2554787
-
A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.Cancer Res. 2000 Oct 15;60(20):5848-56. Cancer Res. 2000. PMID: 11059782
-
Tumor progression in melanoma: the biology of epidermal melanocytes in vitro.Carcinog Compr Surv. 1989;11:369-86. Carcinog Compr Surv. 1989. PMID: 2646021 Review.
-
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.Cancer Res. 1985 Nov;45(11 Pt 2):5670-6. Cancer Res. 1985. PMID: 4053039
-
Biology of tumor progression in human melanocytes.Lab Invest. 1987 May;56(5):461-74. Lab Invest. 1987. PMID: 3553733 Review.
Cited by
-
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.PLoS One. 2012;7(9):e45492. doi: 10.1371/journal.pone.0045492. Epub 2012 Sep 20. PLoS One. 2012. PMID: 23029050 Free PMC article.
-
Quantitative analysis of tumour spheroid structure.Elife. 2021 Nov 29;10:e73020. doi: 10.7554/eLife.73020. Elife. 2021. PMID: 34842141 Free PMC article.
-
Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression.Clin Exp Metastasis. 1995 Jul;13(4):303-14. doi: 10.1007/BF00133486. Clin Exp Metastasis. 1995. PMID: 7606893
-
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.Expert Opin Ther Targets. 2010 Apr;14(4):435-42. doi: 10.1517/14728221003652471. Expert Opin Ther Targets. 2010. PMID: 20230195 Free PMC article. Review.
-
Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm.Am J Pathol. 1992 Sep;141(3):519-24. Am J Pathol. 1992. PMID: 1519660 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials